301 related articles for article (PubMed ID: 26044556)
1. Efficacy and Safety of OM-85 in Patients with Chronic Bronchitis and/or Chronic Obstructive Pulmonary Disease.
Tang H; Fang Z; Saborío GP; Xiu Q
Lung; 2015 Aug; 193(4):513-9. PubMed ID: 26044556
[TBL] [Abstract][Full Text] [Related]
2. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Beeh KM; Beier J; Candler H; Wittig T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
[TBL] [Abstract][Full Text] [Related]
3. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease.
Solèr M; Mütterlein R; Cozma G;
Respiration; 2007; 74(1):26-32. PubMed ID: 16772707
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review.
Sprenkle MD; Niewoehner DE; MacDonald R; Rutks I; Wilt TJ
COPD; 2005 Mar; 2(1):167-75. PubMed ID: 17136978
[TBL] [Abstract][Full Text] [Related]
5. Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation).
Braido F; Melioli G; Cazzola M; Fabbri L; Blasi F; Moretta L; Canonica GW;
Pulm Pharmacol Ther; 2015 Aug; 33():75-80. PubMed ID: 25951945
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections.
Koatz AM; Coe NA; Cicerán A; Alter AJ
Lung; 2016 Aug; 194(4):687-97. PubMed ID: 27117798
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease.
Li J; Zheng JP; Yuan JP; Zeng GQ; Zhong NS; Lin CY
Chin Med J (Engl); 2004 Jun; 117(6):828-34. PubMed ID: 15198881
[TBL] [Abstract][Full Text] [Related]
8. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of OM-85 in managing respiratory tract infections in China.
Xuan J; Wang L; Yin H; Xuan D; Zhou Y; Hu S
J Med Econ; 2015 Mar; 18(3):167-72. PubMed ID: 25275426
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis.
Monz BU; Sachs P; McDonald J; Crawford B; Nivens MC; Tetzlaff K
Respir Med; 2010 Apr; 104(4):534-41. PubMed ID: 19917525
[TBL] [Abstract][Full Text] [Related]
11. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial.
Jara-Pérez JV; Berber A
Clin Ther; 2000 Jun; 22(6):748-59. PubMed ID: 10929921
[TBL] [Abstract][Full Text] [Related]
12. To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial.
Gao J; Gao X; Kong L
Trials; 2014 Apr; 15():150. PubMed ID: 24773830
[TBL] [Abstract][Full Text] [Related]
13. Bacterial lysate add-on therapy to reduce exacerbations in severe asthma: A double-blind placebo-controlled trial.
de Boer GM; Braunstahl GJ; van der Ploeg EK; van Zelst CM; van Bruggen A; Epping G; van Nimwegen M; Verhoeven G; Birnie E; Boxma-de Klerk BM; de Bruijn MJW; Stadhouders R; Hendriks RW; Tramper-Stranders GA
Clin Exp Allergy; 2021 Sep; 51(9):1172-1184. PubMed ID: 34289183
[TBL] [Abstract][Full Text] [Related]
14. Effects of OM-85 BV in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Pan L; Jiang XG; Guo J; Tian Y; Liu CT
J Clin Pharmacol; 2015 Oct; 55(10):1086-92. PubMed ID: 25903441
[TBL] [Abstract][Full Text] [Related]
15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
16. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
[TBL] [Abstract][Full Text] [Related]
17. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant.
Collet JP; Shapiro P; Ernst P; Renzi T; Ducruet T; Robinson A
Am J Respir Crit Care Med; 1997 Dec; 156(6):1719-24. PubMed ID: 9412546
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study.
Wagenlehner FM; Ballarini S; Naber KG
World J Urol; 2014 Dec; 32(6):1595-603. PubMed ID: 24482313
[TBL] [Abstract][Full Text] [Related]
19. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial.
Leuppi JD; Schuetz P; Bingisser R; Bodmer M; Briel M; Drescher T; Duerring U; Henzen C; Leibbrandt Y; Maier S; Miedinger D; Müller B; Scherr A; Schindler C; Stoeckli R; Viatte S; von Garnier C; Tamm M; Rutishauser J
JAMA; 2013 Jun; 309(21):2223-31. PubMed ID: 23695200
[TBL] [Abstract][Full Text] [Related]
20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
